5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.15▲ | 2.14▲ | 2.14▲ | 2.22▼ | 2.18▼ |
MA10 | 2.14▲ | 2.23▼ | 2.24▼ | 2.10▲ | 2.12▲ |
MA20 | 2.23▼ | 2.26▼ | 2.26▼ | 2.13▲ | 1.68▲ |
MA50 | 2.25▼ | 2.11▲ | 2.07▲ | 2.08▲ | 1.50▲ |
MA100 | 2.09▲ | 2.18▲ | 2.18▲ | 1.65▲ | 1.71▲ |
MA200 | 2.25▼ | 2.21▼ | 2.13▲ | 1.54▲ | 4.04▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.007▼ | -0.029▼ | -0.028▼ | 0.011▲ | 0.045▲ |
RSI | 49.186▼ | 49.626▼ | 50.389▲ | 51.760▲ | 57.812▲ |
STOCH | 45.848 | 11.552▼ | 24.771 | 77.370 | 56.857 |
WILL %R | -54.167 | -60.714 | -60.714 | -33.729 | -34.545 |
CCI | 39.194 | -50.309 | -57.093 | 63.311 | 63.229 |
Friday, August 08, 2025 10:53 AM
Discover key insights from Apyx Medical's Q2 2025 earnings: strong AYON presales, new hires, China market entry with Renuvion, and revised revenue guidance.
|
Thursday, August 07, 2025 01:30 PM
Good afternoon, ladies and gentlemen, and welcome to the Apyx Medical Second Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, August 7, 2025. I ...
|
Thursday, August 07, 2025 01:17 PM
Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 2.17 | 2.24 | 2.14 | 2.16 | 45,573 |
14/08/25 | 2.35 | 2.38 | 2.0604 | 2.12 | 146,301 |
13/08/25 | 2.27 | 2.38 | 2.2168 | 2.35 | 37,658 |
12/08/25 | 2.28 | 2.32 | 2.20 | 2.24 | 83,675 |
11/08/25 | 2.18 | 2.3146 | 2.10 | 2.23 | 92,510 |
08/08/25 | 2.20 | 2.20 | 1.78 | 2.18 | 292,429 |
07/08/25 | 2.08 | 2.1192 | 1.931 | 1.96 | 87,306 |
06/08/25 | 1.90 | 2.0879 | 1.90 | 2.04 | 63,705 |
05/08/25 | 1.8604 | 1.99 | 1.825 | 1.91 | 28,904 |
04/08/25 | 1.76 | 1.89 | 1.75 | 1.85 | 40,684 |
|
|
||||
|
|
||||
|
|